{"id":"topical-imiquimod","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Local skin irritation (erythema, edema)"},{"rate":"20-50","effect":"Pruritus"},{"rate":"10-30","effect":"Erosion or ulceration at application site"},{"rate":"5-15","effect":"Systemic flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL1282","moleculeType":"Small molecule","molecularWeight":"240.31"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Imiquimod binds to TLR7 on immune cells, triggering production of interferon-alpha and other pro-inflammatory cytokines. This stimulates both innate and adaptive immune responses, making it effective for treating viral skin lesions and certain skin cancers when applied topically. The local immune activation helps the body recognize and eliminate abnormal cells or viral pathogens.","oneSentence":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to enhance local antiviral and antitumor immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:25.618Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis"},{"name":"Basal cell carcinoma"},{"name":"Genital warts"},{"name":"Superficial skin lesions"}]},"trialDetails":[{"nctId":"NCT07210775","phase":"PHASE1, PHASE2","title":"Topical Imiquimod Treatment of Oral Dysplasia","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2025-10-01","conditions":"Oral Dysplasia, Leukoplakia Oral, Leukoplakia","enrollment":20},{"nctId":"NCT05212246","phase":"PHASE3","title":"Basal Cell Carcinoma Chemoprevention Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Basal Cell Carcinoma","enrollment":1630},{"nctId":"NCT03534947","phase":"PHASE2","title":"A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Melanoma Institute Australia","startDate":"2019-07-23","conditions":"Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified, Skin Cancer","enrollment":16},{"nctId":"NCT03073967","phase":"PHASE3","title":"Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects","status":"COMPLETED","sponsor":"AiCuris Anti-infective Cures AG","startDate":"2017-05-08","conditions":"HSV Infection","enrollment":158},{"nctId":"NCT07251413","phase":"PHASE1, PHASE2","title":"Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Instituto Oncológico Dr Rosell","startDate":"2025-10-22","conditions":"Cutaneous Basal Cell Carcinoma","enrollment":18},{"nctId":"NCT04808245","phase":"PHASE1","title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-02-15","conditions":"Newly Diagnosed H3-mutated Glioma","enrollment":15},{"nctId":"NCT02059499","phase":"PHASE3","title":"Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2015-12-28","conditions":"Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection","enrollment":91},{"nctId":"NCT03370406","phase":"PHASE1","title":"Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC","status":"RECRUITING","sponsor":"Melissa Pugliano-Mauro","startDate":"2018-08-03","conditions":"Carcinoma, Squamous Cell","enrollment":30},{"nctId":"NCT03196180","phase":"EARLY_PHASE1","title":"Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-15","conditions":"Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2","enrollment":13},{"nctId":"NCT06840470","phase":"PHASE4","title":"Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-03-11","conditions":"Sebaceous Hyperplasia","enrollment":40},{"nctId":"NCT02078648","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2014-05","conditions":"Adult Brain Glioblastoma, Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT04883645","phase":"EARLY_PHASE1","title":"Neoadjuvant Imiquimod Immunotherapy for Oral Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2022-04-28","conditions":"Oral Squamous Cell Carcinoma","enrollment":16},{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT04809662","phase":"","title":"Comparing Immune Responses to Topical Imiquimod","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2021-03-16","conditions":"Actinic Keratoses","enrollment":6},{"nctId":"NCT05641545","phase":"PHASE1","title":"IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients","status":"TERMINATED","sponsor":"SLK Kliniken Heilbronn GmbH","startDate":"2022-10-17","conditions":"Advanced Renal Cell Carcinoma","enrollment":1},{"nctId":"NCT02135419","phase":"PHASE3","title":"Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2014-09-24","conditions":"Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection","enrollment":4446},{"nctId":"NCT02394132","phase":"PHASE3","title":"Radiotherapy or Imiquimod in Complex Lentigo Maligna","status":"COMPLETED","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2015-08-31","conditions":"Lentigo Maligna","enrollment":126},{"nctId":"NCT06252857","phase":"","title":"Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2024-04-22","conditions":"Basal Cell Carcinoma","enrollment":142},{"nctId":"NCT05838599","phase":"EARLY_PHASE1","title":"Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-07-24","conditions":"Mycosis Fungoides","enrollment":25},{"nctId":"NCT06305910","phase":"PHASE1","title":"CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults","status":"RECRUITING","sponsor":"OX2 Therapeutics","startDate":"2024-03-15","conditions":"Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma","enrollment":24},{"nctId":"NCT03559413","phase":"PHASE1, PHASE2","title":"Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL","status":"COMPLETED","sponsor":"University Children's Hospital Tuebingen","startDate":"2016-06","conditions":"Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults","enrollment":30},{"nctId":"NCT05405270","phase":"","title":"Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment","status":"RECRUITING","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2022-06-01","conditions":"Cervical High Grade Squamous Intraepithelial Lesion, Cervical Intraepithelial Neoplasia Grade 2/3, CIN 2/3","enrollment":410},{"nctId":"NCT00788164","phase":"PHASE1","title":"Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-11","conditions":"Cervical Cancer, Precancerous Condition, HPV Disease","enrollment":75},{"nctId":"NCT00314756","phase":"PHASE4","title":"Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2005-03","conditions":"Basal Cell Carcinoma","enrollment":15},{"nctId":"NCT05468606","phase":"EARLY_PHASE1","title":"Coadministration of GA2 Sporozoites With Adjuvants","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-02-03","conditions":"Malaria,Falciparum","enrollment":45},{"nctId":"NCT01720407","phase":"PHASE3","title":"Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-12","conditions":"Lentigo Maligna Melanoma (Head or Neck)","enrollment":259},{"nctId":"NCT04219358","phase":"PHASE1","title":"Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis","status":"TERMINATED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2019-03-23","conditions":"Actinic Cheilitis","enrollment":49},{"nctId":"NCT00585247","phase":"NA","title":"Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2006-11","conditions":"Port Wine Stain","enrollment":27},{"nctId":"NCT00142454","phase":"PHASE1","title":"NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2005-08-24","conditions":"Malignant Melanoma","enrollment":9},{"nctId":"NCT01808820","phase":"PHASE1","title":"Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma","status":"COMPLETED","sponsor":"Macarena De La Fuente, MD","startDate":"2013-08-21","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":20},{"nctId":"NCT04083157","phase":"PHASE2, PHASE3","title":"Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-08-12","conditions":"Inflammatory Bowel Diseases, Hepatitis B","enrollment":104},{"nctId":"NCT05314127","phase":"PHASE2","title":"Efficacy of Tazarotene in Treatment of Verruca Plana","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-04-15","conditions":"Warts Flat","enrollment":80},{"nctId":"NCT05315024","phase":"NA","title":"Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-04-30","conditions":"Influenza","enrollment":72},{"nctId":"NCT04279535","phase":"EARLY_PHASE1","title":"Topical Vitamin C for Treatment of Basal Cell Cancer","status":"COMPLETED","sponsor":"Center for Biomedical Research, Inc.","startDate":"2018-03-01","conditions":"Basal Cell Carcinoma","enrollment":25},{"nctId":"NCT05028322","phase":"PHASE2","title":"Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2021-11-01","conditions":"Cirrhosis, Liver, Vaccination Failure, HBV","enrollment":60},{"nctId":"NCT03982004","phase":"PHASE1","title":"Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-09-14","conditions":"Metastatic Breast Cancer","enrollment":1},{"nctId":"NCT04859361","phase":"NA","title":"Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ","status":"UNKNOWN","sponsor":"University Medical Centre Maribor","startDate":"2018-11-20","conditions":"Intraepithelial Neoplasia, Cervical","enrollment":104},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT02301494","phase":"NA","title":"Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma","status":"WITHDRAWN","sponsor":"Rochester General Hospital","startDate":"2020-04","conditions":"Mycosis Fungoides","enrollment":""},{"nctId":"NCT03233412","phase":"PHASE2","title":"Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions","status":"COMPLETED","sponsor":"Barretos Cancer Hospital","startDate":"2018-01-01","conditions":"High Grade Intraepithelial Neoplasia, Cervix Cancer","enrollment":90},{"nctId":"NCT02404389","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-03-05","conditions":"Actinic Keratosis","enrollment":82},{"nctId":"NCT02482428","phase":"PHASE2","title":"Efficacy and Tolerability of Topical LFX453 for External Genital Warts","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-12","conditions":"External Genital Warts","enrollment":88},{"nctId":"NCT03760250","phase":"PHASE2","title":"Imiquimod for Preventing Keloid Recurrence","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2019-02-05","conditions":"Keloid","enrollment":6},{"nctId":"NCT03289260","phase":"PHASE3","title":"Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2021-11-15","conditions":"Anogenital Human Papillomavirus Infection, Condyloma Anal","enrollment":200},{"nctId":"NCT00801320","phase":"NA","title":"Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2008-09","conditions":"Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":100},{"nctId":"NCT00948428","phase":"PHASE3","title":"Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2008-05","conditions":"Actinic Keratoses","enrollment":462},{"nctId":"NCT02293707","phase":"PHASE2","title":"A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Laboratoires Leurquin Mediolanum","startDate":"2014-11","conditions":"Prostate Cancer","enrollment":99},{"nctId":"NCT04072900","phase":"PHASE1","title":"A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-04-21","conditions":"Melanoma (Skin)","enrollment":30},{"nctId":"NCT02224599","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies","status":"TERMINATED","sponsor":"Kiromic BioPharma Inc.","startDate":"2017-07-28","conditions":"Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer","enrollment":3},{"nctId":"NCT03472976","phase":"PHASE1","title":"H5N1 With or Without Topical Aldara in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-06-13","conditions":"Avian Influenza, Influenza Immunisation","enrollment":50},{"nctId":"NCT03901690","phase":"PHASE3","title":"Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study","status":"UNKNOWN","sponsor":"Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri","startDate":"2019-08-27","conditions":"Genital Wart Virus Infection","enrollment":102},{"nctId":"NCT02385188","phase":"PHASE3","title":"Topical 5% Imiquimod Cream for Vulvar Paget's Disease","status":"COMPLETED","sponsor":"University Medical Center Nijmegen","startDate":"2015-05","conditions":"Paget Disease, Extramammary","enrollment":25},{"nctId":"NCT02362152","phase":"","title":"The Real Life Topical Field Treatment of Actinic Keratosis Study","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-07","conditions":"Actinic Keratosis","enrollment":1168},{"nctId":"NCT03307902","phase":"PHASE2, PHASE3","title":"ID HBV Vaccination With Imiquimod in OBI","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-10-01","conditions":"Hepatitis B","enrollment":120},{"nctId":"NCT02621112","phase":"PHASE2, PHASE3","title":"HBV Vaccine in Renal Failure Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-01","conditions":"Renal Failure","enrollment":94},{"nctId":"NCT01191034","phase":"PHASE1, PHASE2","title":"Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2010-08","conditions":"Metastatic Melanoma","enrollment":2},{"nctId":"NCT02454634","phase":"PHASE1","title":"Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas","status":"COMPLETED","sponsor":"National Center for Tumor Diseases, Heidelberg","startDate":"2015-06","conditions":"Glioma","enrollment":39},{"nctId":"NCT00814528","phase":"NA","title":"Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2007-11","conditions":"Actinic Keratosis","enrollment":""},{"nctId":"NCT02917746","phase":"NA","title":"Imiquimod Treatment of High-grade CIN","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2016-11","conditions":"Cervical Intraepithelial Neoplasia","enrollment":120},{"nctId":"NCT02329171","phase":"PHASE3","title":"Imiquimod Treatment of CIN Lesions","status":"TERMINATED","sponsor":"Maastricht University Medical Center","startDate":"2014-12","conditions":"Cervical Intraepithelial Neoplasia","enrollment":9},{"nctId":"NCT00504023","phase":"NA","title":"Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-04","conditions":"Vulvar Cancer","enrollment":8},{"nctId":"NCT00638651","phase":"PHASE1","title":"Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal","status":"COMPLETED","sponsor":"University of Miami","startDate":"2008-02","conditions":"Healthy","enrollment":3},{"nctId":"NCT00979550","phase":"PHASE2","title":"The Effects of Aldara as an Adjunct to Laser Treatment","status":"TERMINATED","sponsor":"Henry Vasconez","startDate":"2008-10","conditions":"Port Wine Stains","enrollment":7},{"nctId":"NCT00821964","phase":"PHASE2","title":"Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-12","conditions":"Male Breast Cancer, Recurrent Breast Cancer, Skin Metastases","enrollment":15},{"nctId":"NCT00944580","phase":"PHASE1","title":"A Vaccine Study for High Risk Cancers","status":"WITHDRAWN","sponsor":"Penn State University","startDate":"2009-06","conditions":"Neuroblastoma, Rhabdomyosarcoma, Osteogenic Sarcoma","enrollment":""},{"nctId":"NCT02281682","phase":"PHASE4","title":"IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2014-11","conditions":"Keratosis, Actinic","enrollment":624},{"nctId":"NCT02960815","phase":"PHASE2","title":"Imiquimod and Influenza Vaccine for Immunocompromised Patients","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2016-11","conditions":"Influenza Vaccine","enrollment":70},{"nctId":"NCT01538901","phase":"PHASE4","title":"Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2012-09","conditions":"Actinic Keratoses","enrollment":10},{"nctId":"NCT03206138","phase":"NA","title":"Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2017-05-30","conditions":"Cervical Intraepithelial Neoplasia 3","enrollment":50},{"nctId":"NCT02130323","phase":"PHASE2, PHASE3","title":"Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix","status":"COMPLETED","sponsor":"United States Naval Medical Center, San Diego","startDate":"2015-02","conditions":"Cervical Intraepithelial Neoplasia","enrollment":22},{"nctId":"NCT03071679","phase":"PHASE1","title":"Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers","status":"COMPLETED","sponsor":"Maruho Co., Ltd.","startDate":"2017-02-06","conditions":"Healthy","enrollment":16},{"nctId":"NCT01059110","phase":"PHASE4","title":"Comparison of Five Treatments in Patients With Plantar Warts","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-02","conditions":"Plantar Warts","enrollment":358},{"nctId":"NCT00865644","phase":"PHASE1","title":"Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-03","conditions":"Neurofibromatosis Type 1, Cutaneous Neurofibromas","enrollment":11},{"nctId":"NCT01264731","phase":"PHASE1","title":"Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2011-01","conditions":"Melanoma","enrollment":4},{"nctId":"NCT00774787","phase":"PHASE4","title":"Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses","status":"COMPLETED","sponsor":"Rigel Dermatology","startDate":"2008-10","conditions":"Actinic Keratoses","enrollment":27},{"nctId":"NCT01283763","phase":"PHASE3","title":"Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2013-05","conditions":"Cervical Intraepithelial Neoplasia","enrollment":95},{"nctId":"NCT00470392","phase":"NA","title":"Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2007-05","conditions":"Psoriasis","enrollment":9},{"nctId":"NCT00031759","phase":"PHASE2","title":"Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1999-06","conditions":"Cervical Cancer, Precancerous Condition","enrollment":57},{"nctId":"NCT00899574","phase":"PHASE2","title":"Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-05","conditions":"Breast Cancer, Breast Neoplasms","enrollment":10},{"nctId":"NCT02052687","phase":"PHASE1","title":"A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01","conditions":"Healthy","enrollment":41},{"nctId":"NCT01788007","phase":"PHASE1","title":"Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2013-01","conditions":"Actinic Keratosis","enrollment":443},{"nctId":"NCT01508884","phase":"NA","title":"Intradermal Trivalent Influenza Vaccine With Imiquimod","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2012-01","conditions":"Chronic Illness","enrollment":93},{"nctId":"NCT00066872","phase":"PHASE3","title":"Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer","status":"COMPLETED","sponsor":"Queen's Medical Center","startDate":"2002-10","conditions":"Non-melanomatous Skin Cancer","enrollment":500},{"nctId":"NCT01935310","phase":"NA","title":"Photoaging Treatment With Imiquimod","status":"COMPLETED","sponsor":"CES University","startDate":"2010-07","conditions":"Photoaging","enrollment":17},{"nctId":"NCT00147771","phase":"PHASE3","title":"Imiquimod in Children With Plaque Morphea","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2005-09","conditions":"Scleroderma, Localized","enrollment":10},{"nctId":"NCT00707174","phase":"NA","title":"Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna","status":"COMPLETED","sponsor":"University of Utah","startDate":"2005-03","conditions":"Cancer, Lentigo Maligna","enrollment":90},{"nctId":"NCT01611480","phase":"PHASE2","title":"Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head","status":"COMPLETED","sponsor":"Moberg Pharma AB","startDate":"","conditions":"Actinic Keratosis","enrollment":""},{"nctId":"NCT01413763","phase":"PHASE4","title":"Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis","status":"UNKNOWN","sponsor":"Medicis Global Service Corporation","startDate":"2011-07","conditions":"Actinic Keratosis","enrollment":50},{"nctId":"NCT01161888","phase":"PHASE4","title":"Effect of Topical Imiquimod on Lentigo Maligna","status":"COMPLETED","sponsor":"Jerry Marsden","startDate":"2010-06","conditions":"Lentigo Maligna","enrollment":30},{"nctId":"NCT01567683","phase":"PHASE1","title":"A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects","status":"COMPLETED","sponsor":"Moberg Pharma AB","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01502020","phase":"NA","title":"A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses","status":"COMPLETED","sponsor":"Actavis Mid-Atlantic LLC","startDate":"2011-02","conditions":"Actinic Keratoses","enrollment":410},{"nctId":"NCT01212562","phase":"","title":"Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery","status":"COMPLETED","sponsor":"University of Ioannina","startDate":"2007-04","conditions":"Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT00204555","phase":"PHASE4","title":"Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2002-01","conditions":"Carcinoma, Basal Cell","enrollment":100},{"nctId":"NCT00735462","phase":"PHASE3","title":"Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2008-08","conditions":"Genital Warts","enrollment":511},{"nctId":"NCT01380314","phase":"PHASE2","title":"Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Foundation Fader","startDate":"2008-03","conditions":"Cutaneous Leishmaniasis","enrollment":60},{"nctId":"NCT00674739","phase":"PHASE3","title":"Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2008-05","conditions":"Genital Warts","enrollment":470},{"nctId":"NCT00941252","phase":"PHASE2, PHASE3","title":"ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2009-07","conditions":"Cervical Intraepithelial Neoplasia","enrollment":60},{"nctId":"NCT01151956","phase":"","title":"Imiquimod and Actinic Keratoses: an Observational Study","status":"COMPLETED","sponsor":"Federal University Teaching Hospital, Feldkirch, Austria","startDate":"2008-05","conditions":"Actinic Keratosis","enrollment":463},{"nctId":"NCT00110682","phase":"PHASE4","title":"Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses","status":"COMPLETED","sponsor":"Derm Research @ 888 Inc.","startDate":"2005-04","conditions":"Keratosis, Actinic Keratosis","enrollment":60},{"nctId":"NCT00384124","phase":"PHASE2, PHASE3","title":"Topical Imiquimod for Bowen's Disease of the Head and Neck","status":"UNKNOWN","sponsor":"Brooke Army Medical Center","startDate":"2006-11","conditions":"Bowens Disease","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":845,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aldara®"],"phase":"phase_3","status":"active","brandName":"Topical Imiquimod","genericName":"Topical Imiquimod","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imiquimod is a small molecule that acts as a Toll-like receptor 7 agonist, classified as an agonist drug. It has been studied for various conditions, including photoaging, warts, basal cell carcinoma, and skin cancer, through clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}